These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25066844)

  • 1. Type I interferon rapidly restricts infectious hepatitis C virus particle genesis.
    Meredith LW; Farquhar MJ; Tarr AW; McKeating JA
    Hepatology; 2014 Dec; 60(6):1891-901. PubMed ID: 25066844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replication.
    Fusco DN; Brisac C; John SP; Huang YW; Chin CR; Xie T; Zhao H; Jilg N; Zhang L; Chevaliez S; Wambua D; Lin W; Peng L; Chung RT; Brass AL
    Gastroenterology; 2013 Jun; 144(7):1438-49, 1449.e1-9. PubMed ID: 23462180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients.
    Martín J; Navas S; Fernández M; Rico M; Pardo M; Quiroga JA; Zahm F; Carreño V
    Antiviral Res; 1999 May; 42(1):59-70. PubMed ID: 10333143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial.
    Berg T; Hoffmann RM; Teuber G; Leifeld L; Lafrenz M; Baumgarten R; Spengler U; Zeuzem S; Pape GR; Hopf U
    Liver; 2000 Dec; 20(6):427-36. PubMed ID: 11169056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
    Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H
    Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.
    Zhu H; Butera M; Nelson DR; Liu C
    Virol J; 2005 Sep; 2():80. PubMed ID: 16146571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
    Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
    Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons.
    Laidlaw SM; Marukian S; Gilmore RH; Cashman SB; Nechyporuk-Zloy V; Rice CM; Dustin LB
    Gastroenterology; 2017 Aug; 153(2):566-578.e5. PubMed ID: 28456632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus.
    Lanford RE; Guerra B; Bigger CB; Lee H; Chavez D; Brasky KM
    Hepatology; 2007 Oct; 46(4):999-1008. PubMed ID: 17668868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry.
    Nguyen LP; Park C; Luong TTD; Park EM; Choi DH; Han KM; Mai HN; Nguyen HC; Lim YS; Hwang SB
    Sci Rep; 2019 May; 9(1):7288. PubMed ID: 31086268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C.
    Hanrotel C; Toupance O; Lavaud S; Thiefin G; Brodard V; Ingrand D; Diebold MD; Wynckel A; Chanard J
    Nephron; 2001 Jun; 88(2):120-6. PubMed ID: 11399913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline sensitivity of T cells to alpha-IFN correlates with sustained virological response to IFN-based triple therapy in HCV infection.
    Sultanik PS; Casrouge A; Alanio C; Mottez E; Rosa-Hézode I; Hézode C; Renard P; Bousquet L; Pellet P; Uzé G; Pol S; Albert ML; Mallet V
    J Viral Hepat; 2015 Jun; 22(6):524-34. PubMed ID: 25382001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.
    Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
    J Infect Chemother; 2012 Oct; 18(5):689-97. PubMed ID: 22450877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple effects of Honokiol on the life cycle of hepatitis C virus.
    Lan KH; Wang YW; Lee WP; Lan KL; Tseng SH; Hung LR; Yen SH; Lin HC; Lee SD
    Liver Int; 2012 Jul; 32(6):989-97. PubMed ID: 22098176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
    Kikuchi K; Akiba T; Nitta K; Masakane I; Ando R; Izumi N; Atsukawa M; Yamazaki C; Kato F; Hotta N; Tominaga Y; Orito E; Hora K; Nagasawa M; Kasahara H; Kawaguchi M; Kimura H; Ikebe N; Kawanishi H; Moriishi M; Shigemoto K; Harada T; Hirakata H; Watanabe H; Nosaki T; Tsubouchi H; Imawari M; Akizawa T
    Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
    Rafique S; Idrees M; Ali A; Iqbal M
    Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatitis C, interferon a and depression: main physiopathologic hypothesis].
    Vignau J; Karila L; Costisella O; Canva V
    Encephale; 2005; 31(3):349-57. PubMed ID: 16142050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro.
    MacParland SA; Pham TN; Guy CS; Michalak TI
    Hepatology; 2009 May; 49(5):1431-41. PubMed ID: 19177592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture.
    Coburn GA; Fisch DN; Moorji SM; de Muys JM; Murga JD; Paul D; Provoncha KP; Rotshteyn Y; Han AQ; Qian D; Maddon PJ; Olson WC
    PLoS One; 2012; 7(4):e35351. PubMed ID: 22545104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.